Trial Profile
Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Ivuxolimab (Primary) ; Utomilumab (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 14 Mar 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
- 14 Mar 2023 Planned primary completion date changed from 30 Sep 2022 to 30 Sep 2024.
- 13 May 2022 Treatments section has been updated and Experimental Arms E and F have been discontinued as per Amendment 9 (02/11/2020).